top of page


Marcos Timón


Marcos Timón is Head of Unit at the Division of Biological Products, Advanced Therapies and Biotechnology within the Spanish Medicines Agency (AEMPS). He is the alternate member for Spain at the Committee for Advanced Therapies (CAT).

After completing his PhD in Spain, Marcos moved to London to work as a postdoctoral scientist at the Tumour Immunology Unit of the Imperial Cancer Research Fund (now Cancer Research UK). He continued his research activities first at the Department of Oncology (University College London) and later at the Edward Jenner Institute for Vaccine Research, also in the UK. He then moved back to Spain to work as Chief Scientific Officer at Mologen Molecular Medicines, a subsidiary of Mologen AG (a biotech company based in Berlin, Germany).

Since joining AEMPS, he has been mostly involved in the quality assessment of medicinal products of biological origin.

Apart from attending the CAT, Marcos is also a member of the Quality Innovation Group, of the WHO Expert Advisory Panel on INN for Advanced Therapies and of other expert groups at national and international level.

bottom of page